NOXXON PHARMA NV (ALNOX.PA) Stock Price, Forecast & Analysis
EPA:ALNOX • NL0012044762
ALNOX.PA Key Statistics, Chart & Performance
The current stock price of ALNOX.PA is 0.041 EUR. In the past month the price decreased by -38.99%. In the past year, price decreased by -88.28%.
ALNOX.PA Technical Analysis
ALNOX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALNOX.PA. ALNOX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALNOX.PA Financial Highlights
Over the last trailing twelve months ALNOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 40.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.9% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALNOX.PA Forecast & Estimates
10 analysts have analysed ALNOX.PA and the average price target is 7.39 EUR. This implies a price increase of 17919.93% is expected in the next year compared to the current price of 0.041.
ALNOX.PA Ownership
ALNOX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 27.61 | 43.863B | ||
| 1AE | ARGENX SE | 27.99 | 43.776B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.869B | ||
| ABVX | ABIVAX SA | N/A | 8.398B | ||
| 2X1 | ABIVAX SA | N/A | 8.382B | ||
| GXE | GALAPAGOS NV | N/A | 1.882B | ||
| GLPG | GALAPAGOS NV | N/A | 1.869B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| IVA | INVENTIVA SA | N/A | 1.092B | ||
| NANO | NANOBIOTIX | N/A | 1.006B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALNOX.PA
Company Profile
NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
Company Info
NOXXON PHARMA NV
Max-Dohrn-Str. 8-10
Berlin BERLIN DE
Employees: 13
Phone: 49307262470.0
NOXXON PHARMA NV / ALNOX.PA FAQ
Can you describe the business of NOXXON PHARMA NV?
NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.
What is the current price of ALNOX stock?
The current stock price of ALNOX.PA is 0.041 EUR. The price decreased by -18% in the last trading session.
Does NOXXON PHARMA NV pay dividends?
ALNOX.PA does not pay a dividend.
How is the ChartMill rating for NOXXON PHARMA NV?
ALNOX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ALNOX stock?
NOXXON PHARMA NV (ALNOX.PA) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ALNOX stock?
NOXXON PHARMA NV (ALNOX.PA) has a market capitalization of 3.05M EUR. This makes ALNOX.PA a Nano Cap stock.